Deals-lir

Subscribe today for access to
Articles and Reports

By Ron Shinkman | Feb 28, 2025 | 1 min read

Becton Dickinson divisions responsible for $3.4 billion in annual revenue are on the block

By Ron Shinkman | Jan 24, 2025 | 1 min read

Quest Diagnostics will find out as it launches a new health coaching business that relies on lab testing, via its Pack Health subsidiary

By Ron Shinkman | Jan 9, 2025 | 1 min read

The company has lost nearly $36 million since 2023, but its CEO is aggressively pursuing new revenue options

By Ron Shinkman | Nov 27, 2024 | 1 min read

The new rules, which were approved by the FTC in October and will go into effect in mid-January, aim to put a damper on consolidation

By Ron Shinkman | Oct 28, 2024 | 1 min read

$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays

By Ron Shinkman | Oct 1, 2024 | 1 min read

The rounds of funding to Clarapath, PreciseDx, and Precision Epigenomics come at a time when other M&A activity is seasonally slow

By Ron Shinkman | Aug 30, 2024 | 1 min read

The roughly $1 billion deal will boost the company’s annual revenue by about 7 percent, and will give Quest a stronger presence in Canada

By Ron Shinkman | Jul 24, 2024 | 1 min read

Though the two national players have closed dozens of such deals over the past decade, much runway for new transactions apparently remains

By Ron Shinkman | Jul 2, 2024 | 1 min read

Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.

By Ron Shinkman | Jun 4, 2024 | 1 min read

Most of Invitae's employees will be hired by Labcorp, which expects the deal to add about $275 million in annual revenue

By Ron Shinkman | May 1, 2024 | 1 min read

Recently announced collaboration between Viome and Henry Schein allows dentists to offer sample collection for Viome’s assay to patients

By Ron Shinkman | Mar 28, 2024 | 1 min read

Partnership between Mindera and PBM aims to optimize treatment matches for the disorder, as some drugs cost nearly six figures annually

By Ron Shinkman | Mar 5, 2024 | 1 min read

Both companies have made recent moves to diversify further.